Potassium-Binding Polymers for Hyperkalemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperkalemia are limited by the need for high doses of exchange resins that cause severe gastrointestinal side effects and are not suitable for outpatient or chronic use, and diuretics are often ineffective due to underlying kidney disease and resistance, particularly in patients with conditions like CHF.
Innovation Solution
Development of potassium-binding polymers with high binding capacity, specifically poly-fluoroacrylic acid polymers crosslinked with divinyl benzene, and core-shell compositions that can selectively bind and remove potassium ions from the gastrointestinal tract, preventing their absorption and excretion, while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If exchange resins such as Kayexalate are used to treat hyperkalemia, then potassium binding capacity is improved, but gastrointestinal side effects and patient compliance deteriorate due to large doses required
Solution Approach 1:
The patent modifies the chemical parameters of exchange resins by incorporating specific functional groups (carboxylic acid, sulfonic acid, phosphonic acid, or polyaminopolycarboxylic acid groups) and controlling the ratio of functional groups to crosslinking groups (0.5:1 to 2:1), thereby achieving higher potassium binding capacity at lower doses and reducing gastrointestinal side effects
Solution Approach 2:
The patent creates composite polymeric materials combining multiple functional groups and crosslinking structures within a single polymer framework, allowing simultaneous optimization of binding capacity and reduced dosage requirements, thereby minimizing harmful gastrointestinal effects
2Quantity of substance
If large doses of exchange resins are administered to achieve adequate potassium binding, then binding capacity is improved, but patient compliance and ease of operation deteriorate
Solution Approach 1:
By changing the chemical composition parameters of the exchange resin (incorporating specific functional groups and crosslinking ratios), the patent achieves higher binding capacity per unit dose, allowing smaller dosages that improve patient compliance and ease of administration
3Productivity
If diuretics are used to remove potassium, then potassium excretion is improved, but efficacy deteriorates due to kidney disease and diuretic resistance
Solution Approach 1:
The patent uses polymeric exchange resins as intermediary substances that bind potassium in the gastrointestinal tract, providing an alternative pathway for potassium removal that bypasses the compromised renal system and avoids diuretic resistance mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The potassium-binding polymers effectively remove potassium ions, reducing serum levels and minimizing side effects, allowing for lower doses and improved patient compliance, making them suitable for both therapeutic and prophylactic use in hyperkalemia management.
Implementation Method 1
an effective amount of a potassium binding polymer is administered to an animal subject, such as a human, the polymer being capable of binding and removing an average of 1.5 mmol or higher of potassium per gm of polymer
Data Source
AI summary
The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.